Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats

By Jieli Chen, Yi Li, Lei Wang, Zhenggang Zhang, Dunyue Lu, Mei Lu, Michael Chopp. Stroke, 2001

1,720 citations recorded by the source corpus.

Subfields: Developmental Neuroscience, Genetics, Neurology

View Paper: https://www.semanticscholar.org/paper/ac364bf7d66581011111c120ea6bca42815455b4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Developmental Neuroscience

1. Michael Chopp
2. Zhenggang Zhang

In Genetics

1. Michael Chopp
2. Yi Li

Citations in the corpus

• MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles (2013, neutral): “After stroke, only a very small percentage of injected MSCs enter the brain which may facilitated by the disruption of the blood-brain barrier [33, 67, 68].”
• Exosome-Mediated Transfer of miR-133b from Multipotent Mesenchymal Stromal Cells to Neural Cells Contributes to Neurite Outgrowth (2012, positive): “MSCs escape immune system surveillance and survive in the CNS even after transplantation of allogeneic [81] or xenogeneic MSCs [52].”
• Autologous mesenchymal stem cell transplantation in stroke patients (2005, background): “After peripheral injection, MSCs cross the blood–brain barrier preferentially in areas that have experienced brain damage.(4,5) Intravenous application of MSCs reduced apoptosis and promoted endogenous cellular proliferation after stroke.”
• Intravenous Administration of Human Bone Marrow Stromal Cells Induces Angiogenesis in the Ischemic Boundary Zone After Stroke in Rats (2003, methodology): “The endothelial cells (2 10(4) cells) were incubated for 3 hours in (1) regular cell culture medium (DMEM), (2) 100% supernatant from 4-day-old hMSC culture, or (3) hMSC supernatant with a rat anti-mouse neutralizing antibody to VEGF receptor 2 (VEGFR2, DC101, 10 g/mL, Imclone System).”
• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, neutral): “Several preclinical animal studies have clearly demonstrated the beneficial effects of MSCs after an ischemic stroke [229,230], although clinical experience is still relatively nascent.”
• Immunobiology of mesenchymal stem cells (2013, background): “ence on MSC effectiveness is the stage of disease: delivery of MSCs at an early stage following an event causing ischemia or EAE has shown enhanced engraftment rates or therapeutic effects, whereas administrated at the relapse stage of EAE, their beneficial effects are reduced.(64,93,113) Finally, t”